A large trial of aspirin use in the adjuvant setting is ongoing which randomizes aspirin use to women with HER2 negative, early stage breast cancers to assess recurrence risk by aspirin use (clinicaltrials.gov #NCT02927249). The gene discussed is ERBB2; the disease is breast carcinoma.